Fig. 1: Changes in treatment recommendations before and after availability of the Recurrence Score result.
From: PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
Rates of hormone therapy alone (HT) or chemo-endocrine therapy (CT+HT) recommendations before testing (Pre RS) and changes in recommendations based on the test resutls (Post RS).
